Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2003 1
2005 1
2011 2
2012 1
2013 1
2019 4
2020 5
2021 3
2022 3
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Discovery and biological evaluation of 1-{2,7-diazaspiro[3.5]nonan-2-yl}prop-2-en-1-one derivatives as covalent inhibitors of KRAS G12C with favorable metabolic stability and anti-tumor activity.
Imaizumi T, Akaiwa M, Abe T, Nigawara T, Koike T, Satake Y, Watanabe K, Kaneko O, Amano Y, Mori K, Yamanaka Y, Nagashima T, Shimazaki M, Kuramoto K. Imaizumi T, et al. Among authors: yamanaka y. Bioorg Med Chem. 2022 Oct 1;71:116949. doi: 10.1016/j.bmc.2022.116949. Epub 2022 Jul 30. Bioorg Med Chem. 2022. PMID: 35926326
Impact of edema on length of calf circumference in older adults.
Ishida Y, Maeda K, Nonogaki T, Shimizu A, Yamanaka Y, Matsuyama R, Kato R, Mori N. Ishida Y, et al. Among authors: yamanaka y. Geriatr Gerontol Int. 2019 Oct;19(10):993-998. doi: 10.1111/ggi.13756. Epub 2019 Aug 8. Geriatr Gerontol Int. 2019. PMID: 31397070
Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression.
Tanaka H, Sakagami H, Kaneko N, Konagai S, Yamamoto H, Matsuya T, Yuri M, Yamanaka Y, Mori M, Takeuchi M, Koshio H, Hirano M, Kuromitsu S. Tanaka H, et al. Among authors: yamanaka y. Mol Cancer Ther. 2019 Aug;18(8):1366-1373. doi: 10.1158/1535-7163.MCT-18-0976. Epub 2019 May 15. Mol Cancer Ther. 2019. PMID: 31092564
Discovery of ASP6918, a KRAS G12C inhibitor: Synthesis and structure-activity relationships of 1-{2,7-diazaspiro[3.5]non-2-yl}prop-2-en-1-one derivatives as covalent inhibitors with good potency and oral activity for the treatment of solid tumors.
Imaizumi T, Shimada I, Satake Y, Yamaki S, Koike T, Nigawara T, Kaneko O, Amano Y, Mori K, Yamanaka Y, Nakayama A, Nishizono Y, Shimazaki M, Nagashima T, Kuramoto K. Imaizumi T, et al. Among authors: yamanaka y. Bioorg Med Chem. 2024 Jan 15;98:117581. doi: 10.1016/j.bmc.2023.117581. Epub 2023 Dec 27. Bioorg Med Chem. 2024. PMID: 38176113
20 results